DOCSLIB.ORG

Desterrando El Término Ewing-Like Sarcoma: ¿Qué Entidades Se Cobijaban Bajo Esa Denominación?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Desterrando El Término Ewing-Like Sarcoma: ¿Qué Entidades Se Cobijaban Bajo Esa Denominación? Desterrando el término Ewing-like sarcoma: ¿Qué entidades se cobijaban bajo esa denominación? Sílvia Bagué Servei de Patologia Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona #SEOM20 No disclosures Small round cell sarcomas (SRCS) - Group of malignant neoplasms sharing histological similar features - Mainly in children & young adults - High-grade by definition. Often “translocated-sarcomas” • Ewing sarcoma • “Ewing-like” sarcomas • Desmoplastic SRCT • Alveolar rhabdomyosarcoma • Poorly diff sinovial sarcoma • Mesenchymal chondrosarcoma • High-grade myxoid liposarcoma • Small cell osteosarcoma • Undiff sarcoma with round cell morphology (USRCS) #SEOM203 Ewing sarcoma • Most common round cell sarcoma • 1st - 2nd decade • 85% diaphysis-metaphysis long bones > pelvis, ribs, chest wall (‘Askin’) • 15% extraeskeletal (adults) • Key morphologic features: uniform monotonous round cells, fine chromatin, inconspicious nucleoli, scant clear to pale cytoplasm • Key immunohistochemical stains: strong and diffuse membranous CD99 expression; NKX2+, PAX7+ • Genetics: fusion between EFT genes (FUS, EWSR1) and TAF15 genes and ETS transcription factor family members (Fli-1, ERG, ETV1, ETV4, FEV, E1AF, ZSG) 85-90% t(11;22)(q24;q12) EWSR1- FLI1 fusion gene 5-10 % t(21;22)(q22;q12) EWSR1-ERG fusion gene CD99 FISH EWSR1 #SEOM204 Desmoplastic small round cell tumor Clinical history Boy, 12 y-o. Intraabdominal mass #SEOM205 DSRCT: IHC & genetics Malignant round cell tumor with desmoplastic stroma, poliphenotypic differentiation and translocation t(11;22)(p13;q12) with EWSR1-WT1 fusion gene WT1 Ker FISH: EWSR1 + Vim DesminDesmin #SEOM206 STT other than Ewing carrying EWS translocation Sbaraglia M et al. Virchows Archiv. 2019 7 Human Molecular Genetics, 2006 Vol.15, No.13 Clin Cancer Res, 2009; 15(7): 2259 Nature Genetics, 2012 Vol.44, No 4 #SEOM208 Classification of soft tissue & bone sarcomas Tumours of uncertain differentiation Acral fibromyxoma Intramuscular myxoma Juxta-articular myxoma Deep (aggressive) angiomyxoma Atypical fibroxanthoma Angiomatoid fibrous histiocytoma Ossifying fibromyxoid tumour Myoepithelioma, myoepithelial carcinoma, and mixed tumour Pleomorphic hyalinizing angiectatic tumour of soft parts Haemosiderotic fibrolipomatous tumour Phosphaturic mesenchymal tumour Synovial sarcoma Epithelioid sarcoma Alveolar soft part sarcoma Clear cell sarcoma of soft tissue Extraskeletal myxoid chondrosarcoma Malignant mesenchymoma Desmoplastic small round cell tumour Extrarenal rhabdoid tumour PEComa Intimal sarcoma Undifferentiated/unclassified sarcomas Undifferentiated round cell EWSR1-non ETS (PATZ1, NFATC2), CIC-DUX4, BCOR Undifferentiated spindle cell sarcoma Undifferentiated pleomorphic sarcoma (UPS) WHO 2013 #SEOM209 Classification of soft tissue & bone sarcomas Tumours of uncertain differentiation Acral fibromyxoma Intramuscular myxoma Juxta-articular myxoma Deep (aggressive) angiomyxoma Atypical fibroxanthoma Angiomatoid fibrous histiocytoma Ossifying fibromyxoid tumour Myoepithelioma, myoepithelial carcinoma, and mixed tumour Pleomorphic hyalinizing angiectatic tumour of soft parts Haemosiderotic fibrolipomatous tumour Phosphaturic mesenchymal tumour Synovial sarcoma Epithelioid sarcoma Alveolar soft part sarcoma Clear cell sarcoma of soft tissue Extraskeletal myxoid chondrosarcoma Malignant mesenchymoma Desmoplastic small round cell tumour Extrarenal rhabdoid tumour PEComa Intimal sarcoma Undifferentiated/unclassified sarcomas ... “ theRound number cell EWSR1 of cases-non with ETS such(PATZ1, fusions NFATC2), is, howeverCIC-DUX4,, stillBCOR small and it remains to be Spindleseen wether cell they represent one or more separate entities, or wether they Pleomorphicare (UPS) better classified as variants of Ewing sarcoma...” “Ewing-like sarcomas” WHO 2013 #SEOM2010 Different molecular profile (RNA sequencing data) Clustering of BCOR-CCNB3 sample (red) with BCOR ITD (orange) and BCOR-MAML3 (purple) into a group, separate from Ess (blue) and CIC-rearranged sarcomas (green) Kao YC et al. Am J Surg Pathol, Vol 42, No 5, May 2018 11 Different molecular profile (DNA methyation) Koelsche et al. Journal of Cancer Research and Clinical Oncology 2019 #SEOM2012 ‘Transcriptomic definition of molecular subgroups of small round cell sarcomas’ New clinical entities or merely “groups” of patients? Watson S et al. J Pathol 2018 May;245(1):29-40. doi: 10.1002/path.5053. 13 Classification of soft tissue & bone sarcomas Tumours of uncertain differentiation Intramuscular myxoma Juxta-articular myxoma Deep (aggressive) angiomyxoma Atypical fibroxanthoma Angiomatoid fibrous histiocytoma Ossifying fibromyxoid tumour Myoepithelioma, myoepithelial carcinoma, and mixed tumour Pleomorphic hyalinizing angiectatic tumour of soft parts Haemosiderotic fibrolipomatous tumour Phosphaturic mesenchymal tumour NTRK-rearranged spindle cell neoplasm (emerging) Synovial sarcoma Epithelioid sarcoma Alveolar soft part sarcoma Clear cell sarcoma of soft tissue Extraskeletal myxoid chondrosarcoma Desmoplastic small round cell tumour Extrarenal rhabdoid tumour PEComa, including angiomyolipoma Intimal sarcoma Undifferentiated sarcoma Undifferentiated small round cell sarcomas of bone and soft tissue Ewing sarcoma Round cell sarcoma with EWSR1-non-ETS fusions CIC-rearranged sarcoma Sarcoma with BCOR genetic alterations WHO 2020 #SEOM2014 CIC - Rearranged Sarcomas • 3-5% round cell sarcomas adult and pediatric population • 70% of SRCSs lacking EWSR1 or FUS rearrangements • CIC gene fusions: CIC-DUX4 (~95%), other partners (5%): LEUTX, DUX10, NUTM1, NUTM2, FOXO4 ... • 90% deep soft tissue (extremities and trunk > retroperitoneum, H&N, visceral) • Bone involvement infrequent (< 5% cases) • Children, young adults (2n decade); slight male predominance • Morphologic features: - Sheets of round cells in a fibrotic to myxoid background - More nuclear atypia, prominent nucleoli “Atypical Ewing sarcomas” - Necrosis (geographic) common. Numerous mitoses - Focal rhabdoid, spindled or epithelioid areas may be present • IHQ: patchy, weak expression for CD99, NKX2.2 -; WT1+, ETV4+ • Molecular diagnosis is challenging (~20-40% false negative results by FISH/ RT-PCR) • Highly aggressive (poorer outcome than ES and BCOR sarcomas) (5-year OS 43%) WT1 ETV4 Carter CD et al. Surg Pathol Clin.2019 doi: 10.106/j.path.2018.10.008 15 Am J Surg Pathol 2017;41:941-949 Source: Sbaraglia M et al. Virchows Archiv. 2019 • Slight male predominance • Peak in 2nd decade • More common in soft tissue Round cell morphology Epithelioid morphology • Trunk > limbs > viscera > bone • Round cell morphology, spindling, epithelioid, myxoid change • CD99 focal • FOXO4, LEUTX, NUTM1, NUTM2A Focal spindling Abundant necrosis 16 Source: Le Loarer F et al. Am J Surg Pathol 2019 17 17 BCOR-Rearranged Round Cell Sarcomas • Uncommon primitive round and spindle cell sarcoma (4% SRCS) • Pediatric and young adult population. Male predominance (85%) • More common in bone (60%). Pelvis, long bones • Various BCOR alterations with different groups/entities: 1. BCOR fusion sarcomas: 90% BCOR-CCNB3 Others: BCOR-MAML3; ZC3H7B-BCOR (HG-ESS, ossifying fibromyxoid tumor) 2. BCOR ITD: Primitive myxoid mesenchymal tumor of infancy / infantile URCS • Morphologic overlap. Key morphologic features: - Delicate branchig capillary network - Myxoid matrix - Mixed round to spindle cells (12% purely spindle. lacking round cells features) • IHC (non-specific): BCOR, BCL-6, cyclin D1, TLE1, SATB2. Overlap with SS!! WT1_ve. CCNB3 (nuclear) in tumors with BCOR-CCNB3 fusion • Treatment? Prognosis: 5-year OS ~ 75% • Better outcome than ES and CIC 18 BCOR-Rearranged Round Cell Sarcomas • Peak in 2nd decade • Male predominance (85%) • More common in bone (2/3) Round cell morphology Spindle cell morphology • Round to spindle cell morphology (between ES and SS) Biphasic morphology BCOR Source: Sbaraglia M et al. Virchows Archiv. 2019 19 BCOR-Rearranged Round Cell Sarcomas BCOR better outcome than ES and CIC Am J Surg Pathol, Vol 42, No 5, May 2018 20 RCS with EWSR1-non ETS fusions EWSR1/NFATc2-rearranged sarcomas • Extremely rare! (56 published cases) [Perret R et al. Modern Pathology 2020] • Strong male predilection (5:1) • 4th decade (older than ES) • Long bones > soft tissue (4:1) • Histology: two patterns A/ cords and clusters of small to medium round cells in a myxohyaline to fibrous matrix (“myoepithelioma- like”) B/ poorly differentiated round cell pattern • CD99 +, CK +, NKX2.2 +,ETV4 -,WT1 -/+ FUS-NFATc2 • Long bones EWSR1–PATZ1 • Deep soft tissue and CNS. Sclerotic. Myogenic markers Source: Sbaraglia M et al. Virchows Archiv. 2019 21 Source: Perret R et al. Modern Pathology 2020#SEOM20 22 Genetics of Ewing sarcoma and “Ewing-like” sarcomas Sbaraglia M et al. Virchows Archiv. 2019 23 ES & “Ewing-like” sarcomas Substantial morphologic overlap... 24 ES CIC BCOR NFATc2 ...but IHC, molecular and clinical differences 25 Clinicopathologic features of round cell sarcomas Davis JL et al. Curr. Treat. Options in Oncol 2020 #SEOM2026 Outcome and common treatment paradigms for round cell sarcomas Davis JL et al. Curr. Treat. Options in Oncol 2020 #SEOM2027 Distribution of gene fusions in Ewing sarcoma and Genes Chromosomes Cancer 2020;59:525–534. round cell sarcoma with EWSR1-non-ETS fusions 28 Clinical data + imaging FNA, CNB Specimen work up FNA CNB H&E Frozen tissue em_sample (biobanking, trials) IHC CD99 TFE3 Molecular pathology Final diagnosis FISH RT- PCR 29 NGS and Sarcomas . Validation of classification - accurate diagnosis provides
Load more

Recommended publications
  • Cardiac Pleomorphic Sarcoma After Placement of Dacron Graft
    Case Report Cardiac pleomorphic sarcoma after placement of Dacron graft Monaliben Patel, MD,a† Walid Saad, MD,b Peter Georges, MD,a George Kaddissi, MD,b omas Holdbrook, MD,c and Priya Singh, MDa Departments of aHematology and Oncology, bCardiology, and cPathology, Cooper University Hospital, Camden, New Jersey rimary cardiac tumors, either benign or malig- the presence of a left atrial tumor. She underwent a nant, are very rare. e combined incidence is transesophageal echocardiogram, which conrmed 0.002% on pooled autopsy series.1 e benign the presence of a large left atrial mass that likely was Ptumors account for 63% of primary cardiac tumors attached to the interatrial septum prolapsing across and include myxoma, the most common, and fol- the mitral valve and was suggestive for recurrent left lowed by papillary broelastoma, broma, and hem- atrial myxoma (Figure 1). e results of a cardiac angioma. e remaining 37% are malignant tumors, catheterization showed normal coronaries. essentially predominated by sarcomas.1 e patient subsequently underwent an excision Although myxoma is the most common tumor of the left atrial tumor with profound internal and arising in the left atrium, we present a case that external myocardial cooling using antegrade blood shows that sarcoma can also arise from the same cardioplegia under mildly hypothermic cardiopul- chamber. In fact, sarcomas could mimic cardiac monary bypass. Frozen sections showed high-grade myxoma.2 e cardiac sarcomas can have simi- malignancy in favor of sarcoma. e hematoxylin lar clinical presentation and more importantly can and eosin stained permanent sections showed sheets share similar histopathological features.
    [Show full text]
  • Soft Tissue Cytopathology: a Practical Approach Liron Pantanowitz, MD
    4/1/2020 Soft Tissue Cytopathology: A Practical Approach Liron Pantanowitz, MD Department of Pathology University of Pittsburgh Medical Center [email protected] What does the clinician want to know? • Is the lesion of mesenchymal origin or not? • Is it begin or malignant? • If it is malignant: – Is it a small round cell tumor & if so what type? – Is this soft tissue neoplasm of low or high‐grade? Practical diagnostic categories used in soft tissue cytopathology 1 4/1/2020 Practical approach to interpret FNA of soft tissue lesions involves: 1. Predominant cell type present 2. Background pattern recognition Cell Type Stroma • Lipomatous • Myxoid • Spindle cells • Other • Giant cells • Round cells • Epithelioid • Pleomorphic Lipomatous Spindle cell Small round cell Fibrolipoma Leiomyosarcoma Ewing sarcoma Myxoid Epithelioid Pleomorphic Myxoid sarcoma Clear cell sarcoma Pleomorphic sarcoma 2 4/1/2020 CASE #1 • 45yr Man • Thigh mass (fatty) • CNB with TP (DQ stain) DQ Mag 20x ALT –Floret cells 3 4/1/2020 Adipocytic Lesions • Lipoma ‐ most common soft tissue neoplasm • Liposarcoma ‐ most common adult soft tissue sarcoma • Benign features: – Large, univacuolated adipocytes of uniform size – Small, bland nuclei without atypia • Malignant features: – Lipoblasts, pleomorphic giant cells or round cells – Vascular myxoid stroma • Pitfalls: Lipophages & pseudo‐lipoblasts • Fat easily destroyed (oil globules) & lost with preparation Lipoma & Variants . Angiolipoma (prominent vessels) . Myolipoma (smooth muscle) . Angiomyolipoma (vessels + smooth muscle) . Myelolipoma (hematopoietic elements) . Chondroid lipoma (chondromyxoid matrix) . Spindle cell lipoma (CD34+ spindle cells) . Pleomorphic lipoma . Intramuscular lipoma Lipoma 4 4/1/2020 Angiolipoma Myelolipoma Lipoblasts • Typically multivacuolated • Can be monovacuolated • Hyperchromatic nuclei • Irregular (scalloped) nuclei • Nucleoli not typically seen 5 4/1/2020 WD liposarcoma Layfield et al.
    [Show full text]
  • Appendix 4 WHO Classification of Soft Tissue Tumours17
    S3.02 The histological type and subtype of the tumour must be documented wherever possible. CS3.02a Accepting the limitations of sampling and with the use of diagnostic common sense, tumour type should be assigned according to the WHO system 17, wherever possible. (See Appendix 4 for full list). CS3.02b If precise tumour typing is not possible, generic descriptions to describe the tumour may be useful (eg myxoid, pleomorphic, spindle cell, round cell etc), together with the growth pattern (eg fascicular, sheet-like, storiform etc). (See G3.01). CS3.02c If the reporting pathologist is unfamiliar or lacks confidence with the myriad possible diagnoses, then at this point a decision to send the case away without delay for an expert opinion would be the most sensible option. Referral to the pathologist at the nearest Regional Sarcoma Service would be appropriate in the first instance. Further International Pathology Review may then be obtained by the treating Regional Sarcoma Multidisciplinary Team if required. Adequate review will require submission of full clinical and imaging information as well as histological sections and paraffin block material. Appendix 4 WHO classification of soft tissue tumours17 ADIPOCYTIC TUMOURS Benign Lipoma 8850/0* Lipomatosis 8850/0 Lipomatosis of nerve 8850/0 Lipoblastoma / Lipoblastomatosis 8881/0 Angiolipoma 8861/0 Myolipoma 8890/0 Chondroid lipoma 8862/0 Extrarenal angiomyolipoma 8860/0 Extra-adrenal myelolipoma 8870/0 Spindle cell/ 8857/0 Pleomorphic lipoma 8854/0 Hibernoma 8880/0 Intermediate (locally
    [Show full text]
  • The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft-Tissue Tumors Julia a Bridge
    Modern Pathology (2014) 27, S80–S97 S80 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors Julia A Bridge Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA Soft-tissue sarcomas are rare, comprising o1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with 4100 benign and malignant soft-tissue tumor entities defined. Not infrequently, these neoplasms exhibit overlapping clinicopathologic features posing significant challenges in rendering a definitive diagnosis and optimal therapy. Advances in cytogenetic and molecular science have led to the discovery of genetic events in soft- tissue tumors that have not only enriched our understanding of the underlying biology of these neoplasms but have also proven to be powerful diagnostic adjuncts and/or indicators of molecular targeted therapy. In particular, many soft-tissue tumors are characterized by recurrent chromosomal rearrangements that produce specific gene fusions. For pathologists, identification of these fusions as well as other characteristic mutational alterations aids in precise subclassification. This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them. Emphasis is placed on the role of molecular pathology in the management of soft-tissue tumors. Familiarity with these genetic events
    [Show full text]
  • Left Atrial Myxoma As a Rare Cause of Cardiogenic Shock in Octagerians: Report of a Case and Review of the Literature
    Journal of Cardiology & Cardiovascular Therapy ISSN: 2474-7580 Review Article J Cardiol & Cardiovasc Ther Volume 2 Issue 5 - January 2017 Copyright © All rights are reserved by Stavros Daliakopoulos Dr. med Ph.D DOI: 10.19080/JOCCT.2017.02.555600 Left Atrial Myxoma as a Rare Cause of Cardiogenic Shock in Octagerians: Report of a Case and Review of the Literature Stavros Daliakopoulos Dr.med Ph.D* , Andreas Tselios, Dimitrios Maragiannis, Kanellos Giakoumakis, Konstantinos Konstantinou, Maria Stergiani, Athina Rammou and Sotirios Moraitis Cardiac Surgery Department, Hellenic Army Hospital, Greece Submission: December 27, 2016; Published: January 17, 2017 *Corresponding author: Stavros Daliakopoulos Dr. med Ph.D, Cardiac Surgeon, Joint Corps Armed Forces Cardiac Surgery Dpt. 401 Hellenic Army Hospital, Mesogion Aven. 138 & Katechaki 11525, Athens, Hellas, Tel. ; Email: Abstract Introduction: Cardiogenic Shock (CS) is a state of end-organ hypo perfusion due to cardiac failure. It occurs in 5% to 8% of patients hospitalized with ST- elevation myocardial infarction (STEMI). Although myocardial infarction with left ventricle failure remains the most common cause of CS, it is crucial to exclude or / and identify rare pathologies that mimic this condition. Left atrial myxoma is the most common benign primary tumor of the heart, accounting for up to 50% of primary cardiac tumors. CS or even sudden cardiac death due to myxomas may result from either complete obstructionCase Presentation: of the mitral valve orifice or MI resulting from coronary artery emboli. We report a patient admitted to our department because of syncopal episode and altered mental status due to a large left atriumConclusion: myxoma. The patient was treated surgically, the myxoma was removed and the systemic manifestations of organ malperfusion were reversed.
    [Show full text]
  • Aggressive Angiomyxoma in Pregnancy: a Rare and Commonly Misdiagnosed Entity Kamal Malukani, Amit V
    Published online: 2020-02-19 Case Report Access this article online Quick Response Code: Aggressive angiomyxoma in pregnancy: A rare and commonly misdiagnosed entity Kamal Malukani, Amit V. Varma, Devashish Choudhary, Shilpi Dosi Website: www.jlponline.org Abstract: DOI: 10.4103/JLP.JLP_179_17 Aggressive angiomyxoma (AAM) is an uncommon mesenchymal tumor that predominantly involves the pelvis and perineum of young females. It is often clinically mistaken for more common superficial lesions such as vaginal cysts, labial cysts, and lipomas. A review of the medical literature reveals very few cases of AAM reported in pregnancy. We describe a rare case of AAM in pregnancy, clinically misdiagnosed as prolapsed cervical fibroid. Key words: Aggressive angiomyxoma, mesenchymal tumors, pregnancy Introduction (G2 P1 L1), married for 5 years, presented with bleeding per vagina for 3 days. She ggressive angiomyxoma (AAM) is also complained of huge mass coming out Aa rare mesenchymal neoplasm of of vagina, difficulty in walking, and pain vulvo‑perineal region and usually found in abdomen and lower back. There was [1] in women of reproductive age group. It no history of fever, weight loss, trauma, is a slow‑growing, low‑grade neoplasm bowel or bladder disturbance, and use of but is locally infiltrative, and relapse any contraceptive. Her menstrual history has been reported in about 30%–40% of and past history were unremarkable. Local cases even after many years of complete examination showed a large pedunculated, resection.[2] Rarely, AAM can metastasize well‑circumscribed, ulcerated mass coming to lungs, peritoneum, and lymph nodes.[3] out of the vagina. Only a few cases of AAM coexistent Ultrasound of abdomen showed with pregnancy are reported in medical bulky anteverted uterus, measuring literature.[4,5] AAM grows to a huge size 9.6 cm × 7.6 cm × 5.4 cm.
    [Show full text]
  • The 2020 WHO Classification of Soft Tissue Tumours: News and Perspectives
    PATHOLOGICA 2021;113:70-84; DOI: 10.32074/1591-951X-213 Review The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives Marta Sbaraglia1, Elena Bellan1, Angelo P. Dei Tos1,2 1 Department of Pathology, Azienda Ospedale Università Padova, Padova, Italy; 2 Department of Medicine, University of Padua School of Medicine, Padua, Italy Summary Mesenchymal tumours represent one of the most challenging field of diagnostic pathol- ogy and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis and, as a consequence, of therapeutic options. The recent publica- tion of the new WHO classification of Soft Tissue Tumours and Bone represents a major step toward improved standardization of diagnosis. Importantly, the 2020 WHO classi- fication has been opened to expert clinicians that have further contributed to underline the key value of pathologic diagnosis as a rationale for proper treatment. Several rel- evant advances have been introduced. In the attempt to improve the prediction of clinical behaviour of solitary fibrous tumour, a risk assessment scheme has been implemented. NTRK-rearranged soft tissue tumours are now listed as an “emerging entity” also in con- sideration of the recent therapeutic developments in terms of NTRK inhibition. This deci- sion has been source of a passionate debate regarding the definition of “tumour entity” as well as the consequences of a “pathology agnostic” approach to precision oncology. In consideration of their distinct clinicopathologic features, undifferentiated round cell sarcomas are now kept separate from Ewing sarcoma and subclassified, according to the underlying gene rearrangements, into three main subgroups (CIC, BCLR and not Received: October 14, 2020 ETS fused sarcomas) Importantly, In order to avoid potential confusion, tumour entities Accepted: October 19, 2020 such as gastrointestinal stroma tumours are addressed homogenously across the dif- Published online: November 3, 2020 ferent WHO fascicles.
    [Show full text]
  • MR Imaging of Aggressive Angiomyxoma of the Female Pelvis: Case Report
    MR Imaging of Aggressive Angiomyxoma of the Female Pelvis: Case Report Hye Mi Kim1, Ji Eun Pyo2, Nam Hoon Cho2, Nam Kyu Kim3, and Myeong-Jin Kim1 Aggressive angiomyxoma is a rare tumor that predominantly occurs in the female genital tract. Because of its high tendency for local recurrence, preoperative diagnosis is important to ensure wide excision and reduce recurrence risk. But it is often misdiagnosed due to its rarity. We present two cases of aggressive angiomyxoma: a recurrent case that was initially misdiagnosed and a preoperatively diagnosed case. Index words : Myxoma Magnetic resonance (MR) Vulva Female Perineum Case 1 Introduction A 43-year-old woman presented with a non tender mass in the right perirectal area in 1999. Magnetic Aggressive angiomyxoma is a recently characterized resonance (MR) imaging showed a large soft-tissue, 12 benign mesenchymal tumor occurring predominantly ×8×5 cm mass, mainly located at the right perineum in the perineal area, with a strong female extending to the perirectal space. The mass displaced predominance in the 3rd-5th decades of life (1). It has a the adjacent soft tissue and splitted the internal and high propensity for local recurrence, thus preoperative external right levator ani sphincter muscle. It was diagnosis is important for planning surgical isointense to muscle on T1-wighted and hyperintense management (2). But it has been often misdiagnosed on T2-weighted images, with a whirling pattern (Fig. 1). due to its rarity (3). Differential diagnosis included a neurogenic tumor, To our knowledge, the imagings of aggressive myxoid liposarcoma, angiomyolipoma or other soft angiomyxoma have not been reported in Korea.
    [Show full text]
  • Cellular Angiofibroma: a Rare Vulvar Neoplasm Distinct from Aggressive Angiomyxoma Jasvinder Kaur Bhatia*1, R Nangia2
    Case Report Cellular Angiofibroma: A Rare Vulvar Neoplasm Distinct From Aggressive Angiomyxoma Jasvinder Kaur Bhatia*1, R Nangia2 1Department of Pathology, Armed Forces Medical college Pune, India 2SR Adv Pathology, CHCC Lucknow, India Keywords: Cellular Angiofibroma, Vulva, Immunohistochemistry, Aggressive Angiomyxoma. ABSTRACT Cellular angiofibroma (CA) is a rare benign mesenchymal neoplasm of the genital region of both the genders. In women, it arises in late reproductive age and can be cured by complete local excision. It is characterized by a bland spindle cell population and numerous small- to medium-sized vessels with hyalinization. We report a rare case in a postmenopausal woman with a view to highlight the importance of differentiating it from similar more aggressive tumours like aggressive angiomyxoma. A 56 year old woman presented with superficial painless swelling of the vulva and the mass was surgically excised. Histological examination revealed spindle cell proliferation and hyalinised blood vessels in a loosely cellular stroma. Immunohistochemistry revealed positivity for vimentin and CD34 and positivity for ER & PR. *Corresponding author: Dr Jasvinder Kaur Bhatia, Department of Pathology, Armed Forces Medical College, Pune-40, India Phone: +91 - 8552825142 E-mail: [email protected] This work is licensed under the Creative Commons Attribution 4.0 License. Published by Pacific Group of e-Journals (PaGe) C-214 Cellular Angiofibroma Introduction Immunohistochemistry: The tumour cells were positive Cellular Angiofibroma (CA) is a rare benign mesenchymal for vimentin and CD34, ER and PR. (Fig 4, 5, 6, 7) The neoplasm of the genital region of both the genders. It arises tumour was negative for S-100 protein, actin, desmin and in women of late reproductive age [1, 2] and can be cured EMA.
    [Show full text]
  • Conversion of Morphology of ICD-O-2 to ICD-O-3
    NATIONAL INSTITUTES OF HEALTH National Cancer Institute to Neoplasms CONVERSION of NEOPLASMS BY TOPOGRAPHY AND MORPHOLOGY from the INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY, SECOND EDITION to INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY, THIRD EDITION Edited by: Constance Percy, April Fritz and Lynn Ries Cancer Statistics Branch, Division of Cancer Control and Population Sciences Surveillance, Epidemiology and End Results Program National Cancer Institute Effective for cases diagnosed on or after January 1, 2001 TABLE OF CONTENTS Introduction .......................................... 1 Morphology Table ..................................... 7 INTRODUCTION The International Classification of Diseases for Oncology, Third Edition1 (ICD-O-3) was published by the World Health Organization (WHO) in 2000 and is to be used for coding neoplasms diagnosed on or after January 1, 2001 in the United States. This is a complete revision of the Second Edition of the International Classification of Diseases for Oncology2 (ICD-O-2), which was used between 1992 and 2000. The topography section is based on the Neoplasm chapter of the current revision of the International Classification of Diseases (ICD), Tenth Revision, just as the ICD-O-2 topography was. There is no change in this Topography section. The morphology section of ICD-O-3 has been updated to include contemporary terminology. For example, the non-Hodgkin lymphoma section is now based on the World Health Organization Classification of Hematopoietic Neoplasms3. In the process of revising the morphology section, a Field Trial version was published and tested in both the United States and Europe. Epidemiologists, statisticians, and oncologists, as well as cancer registrars, are interested in studying trends in both incidence and mortality.
    [Show full text]
  • Table of Contents
    CONTENTS 1. Specimen evaluation 1 Specimen Type. 1 Clinical History. 1 Radiologic Correlation . 1 Special Studies . 1 Immunohistochemistry . 2 Electron Microscopy. 2 Genetics. 3 Recognizing Non-Soft Tissue Tumors. 3 Grading and Prognostication of Sarcomas. 3 Management of Specimen and Reporting. 4 2. Nonmalignant Fibroblastic and Myofibroblastic Tumors and Tumor-Like Lesions . 7 Nodular Fasciitis . 7 Proliferative Fasciitis and Myositis . 12 Ischemic Fasciitis . 18 Fibroma of Tendon Sheath. 21 Nuchal-Type Fibroma . 24 Gardner-Associated Fibroma. 27 Desmoplastic Fibroblastoma. 27 Elastofibroma. 34 Pleomorphic Fibroma of Skin. 39 Intranodal (Palisaded) Myofibroblastoma. 39 Other Fibroma Variants and Fibrous Proliferations . 44 Calcifying Fibrous (Pseudo)Tumor . 47 Juvenile Hyaline Fibromatosis. 52 Fibromatosis Colli. 54 Infantile Digital Fibroma/Fibromatosis. 58 Calcifying Aponeurotic Fibroma. 63 Fibrous Hamartoma of Infancy . 65 Myofibroma/Myofibromatosis . 69 Palmar/Plantar Fibromatosis. 80 Lipofibromatosis. 85 Diffuse Infantile Fibromatosis. 90 Desmoid-Type Fibromatosis . 92 Benign Fibrous Histiocytoma (Dermatofibroma). 98 xi Tumors of the Soft Tissues Non-neural Granular Cell Tumor. 104 Neurothekeoma . 104 Plexiform Fibrohistiocytic Tumor. 110 Superficial Acral Fibromyxoma . 113 Superficial Angiomyxoma (Cutaneous Myxoma). 118 Intramuscular Myxoma. 125 Juxta-articular Myxoma. 128 Aggressive Angiomyxoma . 128 Angiomyofibroblastoma. 135 Cellular Angiofibroma. 136 3. Fibroblastic/Myofibroblastic Neoplasms with Variable Biologic Potential.
    [Show full text]
  • Bone and Soft Tissue Pathology Specimens and 127 Surgicals (Biopsies and Resections)
    ANNUAL MEETING ABSTRACTS 11A the morphologic spectrum and etiology of DAD encountered during adult autopsy in (non-EWSR1) NR4A3 gene fusions (TAF15, TCF12) showed distinctive plasmacytoid an inner city teaching hospital. The diagnostic utility of post mortem lung culture was / rhabdoid morphology, with increased cellularity, cytologic atypia and high mitotic also evaluated. counts. Follow-up showed that only 1 of 16 patients with EWSR1-rearranged tumors Design: A retrospective study was performed on all adult autopsies from July 2010 to died of disease, in contrast to 3 of 7 (43%) patients with TAF15–rearranged tumors. July 2013 with fi nal histopathologic diagnosis of DAD. The histopathological features Conclusions: In conclusion, EMCs with variant NR4A3 gene fusions show a higher of DAD were re-evaluated by one autopsy pathologist and one pathology resident, incidence of rhabdoid phenotype, high grade morphology and a more aggressive based on the duration (exudative or proliferative phase), severity (bilateral/unilateral; outcome compared to the more common EWSR1-NR4A3 positive tumors. Furthermore, focal/extensive) and pattern (classical vs. acute fi brinous and organizing pneumonia as EWSR1 FISH break-apart assay is the preferred ancillary test to confi rm diagnosis aka AFOP). Clinical history, pre and post mortem laboratory investigations, including of EMC, tumors with variant NR4A3 gene fusions remain under-recognized and often postmortem lung culture (for bacteria, mycobacteria, fungi and virus) were reviewed misdiagnosed. FISH assay for NR4A3 rearrangements recognizes >95% of EMCs and to elucidate etiology. should be an additional tool in EWSR1-negative tumors. Results: 36 (16.2 %) cases showed histopathologic features of DAD out of 222 adult autopsies in the three year study period.
    [Show full text]